Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparano

Showing results (111-120 of 293) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change DecisionsJinani Jayasekera, Joseph A Sparano, Suzanne O'Neill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205T Li, P J Christos, J A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast CancerJesus D Anampa, Daniel L Flynn, Cynthia Leary, et al.
Breast Cancer Research and Treatment|December 4, 2010
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studiesHenri Roché, Pierfranco Conte, Edith A Perez, et al.
Clinical Breast Cancer|March 17, 2004
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancerJoshua P Raff, Lakshmi Rajdev, Umekalsoom Malik, et al.
Journal of Geriatric Oncology|January 30, 2014
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerLinda T Vahdat, Eduard Vrdoljak, Henry Gómez, et al.
Meta Gene|May 26, 2015
Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugsScooter Willis, Pradip De, Nandini Dey, et al.
Seminars in Oncology|June 1, 1995
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancerG W Sledge, N Robert, J A Sparano, et al.
Seminars in Oncology|October 1, 1994
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experienceG W Sledge, N Robert, J A Sparano, et al.
Breast Cancer Research and Treatment|March 25, 2010
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198Antonio C Wolff, Molin Wang, Hailun Li, et al.
Pageof 30

Showing results (111-120 of 293) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change DecisionsJinani Jayasekera, Joseph A Sparano, Suzanne O'Neill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205T Li, P J Christos, J A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast CancerJesus D Anampa, Daniel L Flynn, Cynthia Leary, et al.
Breast Cancer Research and Treatment|December 4, 2010
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studiesHenri Roché, Pierfranco Conte, Edith A Perez, et al.
Clinical Breast Cancer|March 17, 2004
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancerJoshua P Raff, Lakshmi Rajdev, Umekalsoom Malik, et al.
Journal of Geriatric Oncology|January 30, 2014
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerLinda T Vahdat, Eduard Vrdoljak, Henry Gómez, et al.
Meta Gene|May 26, 2015
Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugsScooter Willis, Pradip De, Nandini Dey, et al.
Seminars in Oncology|June 1, 1995
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancerG W Sledge, N Robert, J A Sparano, et al.
Seminars in Oncology|October 1, 1994
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experienceG W Sledge, N Robert, J A Sparano, et al.
Breast Cancer Research and Treatment|March 25, 2010
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198Antonio C Wolff, Molin Wang, Hailun Li, et al.
Pageof 30